J Virol, August 1998, p. 6398-6405, Vol. 72, No. 8
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Department of Medical Biochemistry and Microbiology, Biomedical Centre, Uppsala University, Uppsala, Sweden
Received 10 November 1997/Accepted 17 April 1998
| |
ABSTRACT |
|---|
|
|
|---|
The rotavirus nonstructural phosphoprotein NSP5 is encoded by a gene in RNA segment 11. Immunofluorescence analysis of fixed cells showed that NSP5 polypeptides remained confined to viroplasms even at a late stage when provirions migrated from these structures. When NSP5 was expressed in COS-7 cells in the absence of other viral proteins, it was uniformly distributed in the cytoplasm. Under these conditions, the 26-kDa polypeptide predominated. In the presence of the protein phosphatase inhibitor okadaic acid, the highly phosphorylated 28- and 32- to 35-kDa polypeptides were formed. Also, the fully phosphorylated protein had a homogeneous cytoplasmic distribution in transfected cells. In rotavirus SA11-infected cells, NSP5 synthesis was detectable at 2 h postinfection. However, the newly formed 26-kDa NSP5 was not converted to the 28- to 35-kDa forms until approximately 2 h later. Also, the protein kinase activity of isolated NSP5 was not detectable until the 28- and 30- to 35-kDa NSP5 forms had been formed. NSP5 immunoprecipitated from extracts of transfected COS-7 cells was active in autophosphorylation in vitro, demonstrating that other viral proteins were not required for this function. Treatment of NSP5-expressing cells with staurosporine, a broad-range protein kinase inhibitor, had only a limited negative effect on the phosphorylation of the viral polypeptide. Staurosporine did not inhibit autophosphorylation of NSP5 in vitro. Together, the data support the idea that NSP5 has an autophosphorylation activity that is positively regulated by addition of phosphate residues at some positions.
| |
INTRODUCTION |
|---|
|
|
|---|
Rotavirus is the major etiologic agent of gastroenteritis in the young of human and animal species (3). The genome of rotavirus consists of 11 segments of double-stranded RNA. Six of them code for structural proteins, arranged in a core with VP1, VP2, and VP3, an inner shell made of VP6, and an outer shell composed of VP7 and VP4. The rest of the genome segments code for nonstructural proteins (NSP1 through NSP6) present in rotavirus-infected cells but not in virions (18).
Rotavirus NSP5 protein is encoded by the smallest genomic RNA segment. In the simian rotavirus SA11 strain, it is 198 amino acids long. The polypeptide contains 20% serine residues (23). The major intracellular polypeptides have sizes corresponding to 26, 28, and 30 to 35 kDa when resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). This heterogeneous mobility of the protein is due to phosphorylation at multiple sites (1, 5, 29, 32) and reportedly to addition of O-linked GlcNac (11).
NSP5 is phosphorylated at serine and, to a lesser extent, threonine residues. Tryptic mapping and two-dimensional PAGE analysis of the protein indicated that multiple amino acid residues are phosphorylated (1, 5). Recently, it was reported that treatment of the NSP5 polypeptides isolated from infected cells with protein phosphatase 2A (PP2A), calf intestinal phosphatase, or lambda protein phosphatase resulted in dephosphorylation of 28- and 30- to 35-kDa polypeptides and accumulation of the 26-kDa form (1, 5, 29). However, phosphatase treatment did not remove the phosphate groups from the 26-kDa band. Incubation of NSP5 isolated from infected cells with ATP leads to autophosphorylation. The phosphate residues are incorporated chiefly into 28- to 35-kDa polypeptides, just as in infected cells (1, 5, 29). Furthermore, in vitro protein kinase activity has been demonstrated with NSP5 produced in transient transfection with the segment 11 gene, by infection with gene 11 recombinant vaccinia virus or baculovirus and bacterially expressed polypeptide (5, 29). However, in this autophosphorylation reaction the 26-kDa material did not become fully phosphorylated, as judged by the absence of 28- to 35-kDa forms (5, 29). The necessity of a cofactor that could generate full kinase activity of NSP5 in infected cells was suggested (29).
NSP5, together with NSP2 and the structural proteins VP2 and VP6, accumulate in viroplasms, the sites where rotavirus RNA replication and assortment of segments into provirions occur (19, 27, 28). During RNA replication and virion morphogenesis, NSP2 and NSP5 can be isolated in association with replicative intermediate particles (26). However, the function of NSP5 and its protein kinase activity are unknown. In the study described herein, we have analyzed the kinetics of synthesis and phosphorylation of NSP5, both during rotavirus infection of MA104 cells and when expressed from cDNA in transfected COS-7 cells. To investigate whether cellular protein kinases participate in the phosphorylation of NSP5, we tested the effects of several inhibitors on both infected and transfected cells.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Cells and virus. Rhesus monkey kidney MA104 cells and African green monkey kidney COS-7 cells were grown in Dulbecco modified Eagle medium (DMEM) supplemented with 5% fetal calf serum (Gibco BRL). Simian rotavirus strain SA11 clone 3 was obtained from R. F. Ramig (Baylor College of Medicine). MA104 and COS-7 cells were infected with SA11 rotavirus by using a previously described procedure (17). Virus titers were determined by counting cells expressing viral capsid antigen after staining with the immune peroxidase method (2). Titers were expressed as focus-forming units per milliliter.
NSP5 expression in transfected cells. To prepare a recombinant expression plasmid, a DNA fragment containing the NSP5 gene was excised from plasmid pGEX-NSP5 (6), using restriction endonucleases EcoRI and BamHI. The fragment was then inserted into the corresponding cleavage sites of the pcDNA3 vector (Invitrogen) downstream of the cytomegalovirus immediate-early promoter. Subconfluent monolayers of COS-7 cells in 60-mm-diameter petri dishes were transfected with pcDNA3 or pcDNA-NSP5 (2 µg of plasmid DNA per dish), using Lipofectamine (Gibco BRL) according to the supplier's instructions. The cells were harvested after 48 h, proteins were separated by SDS-PAGE, and the NSP5 polypeptides were detected by immunoblotting.
Radioactive labeling and immunoprecipitation of NSP5.
To
label protein with 35S or 32P, MA104 or COS-7
cells were grown in 60-mm-diameter petri dishes. Cultures of infected
and of transfected cells were incubated for 1 and 3 h,
respectively, in methionine-free DMEM supplemented with 50 µCi of
[35S]methionine per ml or in phosphate-free DMEM
supplemented with 200 µCi of 32Pi per ml. For
pulse-chase experiments, the cells were first radioactively labeled,
then rinsed with DMEM, and incubated for the same time period with
regular DMEM. After labeling, the cell monolayers were rinsed with 1 ml
of Tris-buffered saline (20 mM Tris-HCl [pH 7.5], 150 mM NaCl)
containing 50 mM NaF, 0.10 mM Na3VO4, and 1.0 mM dithiothreitol (DTT). The cells were scraped off the surface, transferred to microcentrifuge tubes, and treated for 10 min at 20°C
with 100 µl of TX lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 30 mM NaPPi, 1.0 mM DTT, 10% glycerol, 1.0% Triton X-100, 50 mM NaF, 0.10 mM Na3VO4, 1.0 µg of
aprotinin and 50 µg of phenylmethylsulfonyl fluoride per ml). Nucleic
and cell debris were removed by centrifugation at 20,000 × g for 20 min, and the NSP5 polypeptides were
precipitated from the supernatant with a specific NSP5 antiserum as
previously described (5). These samples, or fractions of TX
lysates not subjected to immunoprecipitation, were mixed with an equal
volume of 2× SDS sample buffer, boiled, and resolved by SDS-PAGE as
described by Laemmli (15). Okadaic acid (Gibco BRL) at 0.5 µM, staurosporine (BIOMOL) at 1.0 mM, and
5,6-dichloro-1-
-D-ribofuranosyl benzimidazole (DRB;
BIOMOL) at 0.2 mM were included during the pulse-labeling or chase
periods in some experiments.
Immunoblotting procedure. Cytosolic proteins of rotavirus-infected MA104 cells or transfected COS-7 cells were extracted with TX lysis buffer for 10 min at 22°C and then clarified by centrifugation. Polypeptides were resolved by SDS-PAGE and transferred to nitrocellulose membranes. After blocking with 5% nonfat milk in phosphate-buffered saline (PBS), membranes were probed with mouse NSP5 antiserum (diluted 1:2,000 in PBS-0.1% milk) for 1 h at 37°C. The membrane with bound specific antibodies was incubated for 1 h at 37°C with peroxidase-conjugated secondary antibodies. Membranes were developed either with diaminobenzidine and photographed or with the Amersham enhanced chemiluminescence detection system. Chemiluminescence of NSP5-related material was quantified with a GS-250 molecular imager (Bio-Rad).
Immunofluorescence microscopy. MA104 cells were grown to semiconfluency on glass coverslips, fixed with 3% paraformaldehyde in PBS at different time points after rotavirus infection, and then stained for NSP5- or VP6-specific immunofluorescence based on a protocol described by Loo et al. (16). Cells were permeabilized with 0.2% Triton X-100, dissolved in PBS, rinsed in PBS, and then incubated with mouse NSP5 antiserum (1:200 dilution in PBS) overnight at 4°C. After washing with PBS, the preparations were blocked with normal goat serum (1:50 dilution in PBS) and then incubated with fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibodies (1:100 dilution in PBS) for 1 h at 4°C. Coverslips with the cells were wet mounted in glycerol containing 2% 1,4-diazabicyclo-(2,2,2)-octane. The slides were visualized in a Nikon Optophot-2 microscope using phase-contrast and fluorescence optics. Images were digitized by using a charge-coupled device camera (Sony Instruments) connected to a computerized image analysis system (software and hardware from Bergströms Instruments, Solna, Sweden). The digitized images were printed with a Sony UP-860/CE video printer.
Assay of protein kinase activity.
Phosphorylation in vitro
was performed with NSP5 protein immunoprecipitated from infected MA104
cells or from transfected COS-7 cells. NSP5 protein immobilized on
protein G-Sepharose beads (Pharmacia) was incubated for 10 min at
20°C in 25 µl of kinase buffer (20 mM HEPES [pH 7.5], 10 mM
MnCl2, 1.0 mM DTT, 5 µM ATP) containing 10 µCi of
[
-32P]ATP. The reactions were stopped by adding 25 µl of 2× SDS sample buffer. The samples were incubated in a boiling
water bath for 5 min before separation of polypeptides by
SDS-PAGE.
| |
RESULTS |
|---|
|
|
|---|
Cellular localization of NSP5. The cellular localization of NSP5 during the infection cycle was examined by immunofluorescence. MA104 cells were infected with simian rotavirus SA11, fixed with paraformaldehyde at different time points postinfection, and then stained for NSP5-specific immunofluorescence (Fig. 1A and B). NSP5 was visible in the cytoplasmic inclusions characteristic of rotavirus infection already 2 h after infection. As the infection proceeded, the viroplasms increased in size and released proviral particles. However, NSP5 remained in the viroplasmic inclusions even late in infection, suggesting that the polypeptide forms part of a structure involved in assortment and replication of rotavirus RNA.
|
Kinetics of synthesis and phosphorylation of NSP5. To quantify the accumulation of NSP5 polypeptide during rotavirus infection of MA104 cells, the polypeptide was analyzed by immunoblotting. In earlier experiments, we extracted protein from cells by using a buffer containing the nonionic detergent Triton X-100. To determine what proportion of NSP5 remained insoluble in cells lysed by this procedure, the extracts were centrifuged at high speed. Polypeptides in both the supernatant and sedimented fractions were then treated with SDS at 100°C under reducing conditions, resolved by SDS-PAGE, and transferred to a membrane. An antiserum raised against bacterially produced purified NSP5 was used to detect the polypeptide expressed in the rotavirus-infected MA104 cells. As previously described (1, 5, 29), multiple bands of NSP5 polypeptides were found at positions corresponding to 26 and 28 kDa and as a smear migrating at 28 to 35 kDa (Fig. 2). The two major bands at 26 and 28 kDa appeared in samples taken at 4 h postinfection. As the infection proceeded, NSP5 accumulated and material migrating at the 30- to 35-kDa position emerged. Late during infection NSP5 synthesis dropped, probably due to the cytopathic effect. The experiment also showed that most of NSP5 was soluble after extraction with Triton X-100 and that the insoluble fraction of the polypeptide did not change during the course of the infection.
|
|
-32P]ATP in protein kinase buffer. The appearance of
NSP5 with protein kinase activity in vitro coincided with the formation
of highly phosphorylated forms of the polypeptide in cells
(Fig. 3, lanes 18 to 20). However, the protein synthesized at 4 h
postinfection had a very low autophosphorylation activity in the
cell-free system. In addition, the in vitro protein kinase activity
remained even at 10 h, when there was practically no synthesis or
phosphorylation of NSP5 in vivo. The low activity early in infection
suggests that efficient autophosphorylation of NSP5 requires a
cofactor(s). Whether this cofactor consists of NSP5 modification or
another polypeptide, we do not know. However, it is unlikely
that a polypeptide factor would coprecipitate with NSP5 at late
but not at early times after infection.
Effect of staurosporine and okadaic acid on NSP5 phosphorylation. NSP5 synthesized early during rotavirus infection was phosphorylated in the infected cells but had very low autophosphorylation activity in vitro (Fig. 3). This result suggests that cellular protein kinases might be involved in the phosphorylation of NSP5. Analysis of the NSP5 amino acid sequence predicted the presence of several recognition sites of protein kinase C and casein kinase II. Therefore, we tested the effects of staurosporine, DRB, and okadaic acid on NSP5 phosphorylation. Staurosporine is a potent inhibitor of protein kinase C (31) and a wide variety of other enzymes of both the serine/threonine and tyrosine kinase families (21). DRB inhibits casein kinase II (34), and okadaic acid is a specific inhibitor of PP1 and PP2A (7). The latter two enzymes are major cytosolic protein phosphatases of mammalian cells with specificity for phosphoserine and phosphothreonine residues (4).
To investigate the effects of the three enzyme inhibitors on NSP5 phosphorylation, either compound was added to the infected cells at different times postinfection during the last 60 min before harvest. Concentrations of the inhibitors
1.0 mM staurosporine, 0.2 mM
DRB, and 0.5 µM okadaic acid
that were just below the cytotoxic level were determined in initial experiments (data not shown). The NSP5 polypeptides extracted from treated cells were
analyzed by SDS-PAGE followed by immunoblotting. To detect newly
synthesized or newly phosphorylated NSP5, material extracted from
cells labeled with [35S]methionine or
32Pi during 1 h immediately before harvest
was immunoprecipitated and then resolved by SDS-PAGE. The amount of
immunoreactive material and the radioactivity at the positions
corresponding to 26, 28, and 30 to 35 kDa were determined.
The influence of treatment with staurosporine for 1 h on the
accumulated amount and isoform distribution of NSP5 was small (Fig.
4), an expected result considering the
stability of the protein. Staurosporine had a moderate effect on newly
synthesized polypeptides and induced a strong decrease of their
phosphorylation. The compound had similar effects at early and late
times after infection, and the inhibition of
32Pi incorporation was more obvious than the
effect on electrophoretic mobility shift. Thus, we conclude that the
effect of staurosporine was to reduce the number of phosphate groups
per polypeptide chain to a somewhat lower value. At the same
time, the inhibitor had a much stronger effect on cellular protein
phosphorylation. Incorporation of 32Pi into
cellular protein decreased by 50 to 60% (data not shown). DRB had no
effect on NSP5 phosphorylation in infected cells, and therefore data
are not shown.
|
Synthesis and phosphorylation of NSP5 in transfected cells. To examine the synthesis and modifications of NSP5 in the absence of other viral protein, the polypeptide was transiently expressed in COS-7 cells after transfection with the recombinant plasmid pcDNA-NSP5. Transfected COS-7 cells were incubated for 48 h before protein was pulse-labeled with [35S]methionine or 32Pi for 3 h. Extracted NSP5 was immunoprecipitated and analyzed by SDS-PAGE. A 26-kDa polypeptide labeled with 35S or 32P was synthesized in cells transfected with pcDNA-NSP5 (Fig. 5, lane 3). However, although this polypeptide was stable during a 3-h chase period, more slowly migrating NSP5 polypeptides did not appear (Fig. 5, lane 4). When the transfected cells were incubated with okadaic acid, to inhibit protein phosphatases during the labeling period, NSP5 was apparently protected from dephosphorylation and shifted in size to 28 to 35 kDa (Fig. 5, lane 6). When protein was labeled in the absence of inhibitor and the label was chased in the presence of okadaic acid, the shift to the 30- to 35-kDa position was even more pronounced (Fig. 5, lane 5). Conversely, some of the 30- to 35-kDa material formed in the presence of okadaic acid disappeared when the pulse-chase was performed in the absence of the inhibitor (Fig. 6, lanes 6 to 8).
|
|
Effect of protein kinase inhibitors on NSP5 expression in transfected cells. Protein kinase inhibitors were added during labeling with 32Pi to investigate their effect on NSP5 phosphorylation in COS-7 cells transfected with pcDNA-NSP5. The cells were treated with 0.5 µM okadaic acid before and during the incubation with protein kinase inhibitors, to allow the formation of all NSP5 isoforms (Fig. 6, lane 3). NSP5 phosphorylation decreased significantly when the cells were treated for 3 h with 1.0 mM staurosporine (Fig. 6, lane 4). The inhibition of NSP5 phosphorylation appeared to be stronger in the transfected cells than in cells infected with rotavirus (Fig. 4).
The adenosine analog DRB did not inhibit NSP5 phosphorylation in the transfected cells (Fig. 6, lane 5), consistent with the absence of effect in infected cultures. These results indicate that casein kinase II is not involved in NSP5 phosphorylation. In contrast, DRB partially inhibited NSP5 autophosphorylation in vitro (see below).Effect of NSP5 phosphorylation and protein kinase inhibitors on
autophosphorylation in vitro.
Since the NSP5 protein expressed in
COS-7 cells was phosphorylated independently of other viral proteins,
we investigated whether it maintained this ability in vitro. To obtain
highly phosphorylated NSP5 polypeptides, protein phosphatase
activity was inhibited with okadaic acid as described above.
Polypeptides from cell extracts resolved by SDS-PAGE were first
analyzed by immunoblotting, to verify that NSP5 was expressed and
modified in the COS-7 cells. As a control, NSP5 produced during a 6-h
infection of MA104 and COS-7 cells by rotavirus SA11 was included in
the experiment (Fig. 7A). To test protein
kinase activity in vitro, immunoprecipitated NSP5 protein immobilized
on protein G-Sepharose beads was incubated in kinase buffer containing
10 µCi of [
-32P]ATP. The reaction products were
separated by SDS-PAGE and identified by autoradiography. Figure
7B shows that the 26-kDa NSP5 produced in
transfected cells had a weak autophosphorylation activity. Still,
there was a large amount of 26-kDa NSP5, as judged by the amount
of protein detected in the immunoblot (Fig. 7A). When the same
experiment was performed with the NSP5 polypeptides isolated from transfected cells treated with okadaic acid, or isolated from
rotavirus-infected MA104 or COS-7 cells, all forms of NSP5 were
modified (Fig. 7, lanes 4, 7, and 9). However, larger forms of the
polypeptide contained most of the phosphate. When the
transfected cells were incubated with okadaic acid for 3 h and
then removed from phosphatase inhibition for another 3 h before
harvest, the amount of highly phosphorylated NSP5 decreased, with a
concomitant increase of 26- to 28-kDa forms (Fig. 5). The isolated NSP5
showed a parallel distribution of 32P incorporation from
autophosphorylation in vitro (Fig. 7, lane 5). Hence, this activity of
NSP5 in cells and in vitro appeared to be related to the number of
phosphate residues already incorporated.
|
-32P]ATP and MnCl2 were then added, and
incubation was continued for 20 min. Analysis of 32P
incorporation into polypeptides separated by SDS-PAGE showed (Fig. 8) that staurosporine had little
effect. In contrast, DRB decreased the autophosphorylation of NSP5 in
this cell-free system by more than 50%. The effect of the casein
kinase II inhibitor DRB was unexpected, since the compound did not
inhibit NSP5 phosphorylation in cells.
|
| |
DISCUSSION |
|---|
|
|
|---|
NSP5 accumulates together with VP6 in viroplasms (28). The work presented here shows that the viroplasms gradually increased in size during infection and that NSP5 remained in these structures (Fig. 1), suggesting that it forms part of a scaffold for the early steps of virion morphogenesis. However, NSP5 alone cannot be the viroplasm organizer, since expression of the polypeptide in the absence of the other rotavirus gene products did not lead to formation of viroplasm-like inclusions (Fig. 1). Instead, material reactive with NSP5 antibodies formed a diffuse staining in the cytoplasm, even when the posttranslational modification of the polypeptides apparently was the same as in infected cells (Fig. 5 and 7).
The present experiments provide further evidence that phosphorylation of NSP5 is not a determinant for the localization of the polypeptide. Labeling with [35S]methionine and immunoblot analysis showed NSP5 formation at 2 h postinfection. The immunoreactive material was located in viroplasms (Fig. 1). Phosphorylation of NSP5 as determined by labeling with 32Pi became detectable at 2 to 4 h after infection, approximately 2 h after synthesis of the polypeptide. Thus, phosphorylation of NSP5 did not appear to be necessary for its localization in viroplasms. Similarly, rotavirus NSP2 expressed in the absence of other viral proteins did not accumulate in cytoplasmic inclusions, as it does in infected cells (14). The establishment of the viroplasm structure may require interaction between several viral proteins (28).
All phosphorylated forms of NSP5 (26, 28, and 30 to 35 kDa) accumulating in viroplasms were observed only in cells infected with rotavirus. In COS-7 cells expressing NSP5 from a plasmid DNA vector, only the 26-kDa form appeared, and it had a diffuse cytoplasmic distribution. However, extensive phosphorylation of NSP5, leading to a series of phosphorylated polypeptides as in infected cells, was achieved without expression of the other rotavirus proteins. The critical factor appeared to be removal from NSP5 of newly added phosphate groups by phosphatases. In the presence of the phosphatase inhibitor okadaic acid, the phosphorylated NSP5 forms were stable for several hours.
Okadaic acid increased the phosphorylation of NSP5 also in rotavirus-infected cells. However, the relative effect was much less than with NSP5 expressed from a vector. This result indicates that the viroplasms are sites protected from the activities of cellular phosphatases and possibly other cellular enzymes.
In a previous study of NSP5 processing (32), protein was pulse-labeled with [35S]methionine for 10 min and then chased for 40 min with unlabeled methionine. During the chase period, most of the labeled 26-kDa polypeptide was transferred to the 28-kDa position. We extended that study by analyzing the phosphorylation of NSP5 at different times postinfection. At all time points after infection, most of the 26-kDa polypeptide labeled with [35S]methionine during 60 min was processed to the 28-kDa, and some to the 30- to 35-kDa, form during the following hour. In contrast, NSP5 that had incorporated 32P label during a 60-min pulse remained essentially stable. Neither the amount of radioactivity nor the electrophoretic mobility of the labeled polypeptide changed during a 60-min chase period, indicating that a number of stable phosphorylated NSP5 forms exist. Apparently, 26-kDa material is processed to both 28- and 30- to 35-kDa forms. However, at least the majority of 28-kDa NSP5 is not an intermediate used for further phosphorylation.
Purified NSP5 isolated from rotavirus-infected cells, or other eukaryotic or bacterial cells expressing the protein, is capable of autophosphorylation (1, 5, 29). However, the activity of the purified protein isolated from bacteria has low activity and does not add more than one phosphate residue per polypeptide chain (5, 29). Thus, at present it is unclear whether cellular protein kinases also participate in NSP5 phosphorylation. Considering that the autophosphorylation activity of 26-kDa NSP5 is quite low and that there are several recognition sites of protein kinase C and casein kinase II in NSP5 (5), these two enzymes might participate in the phosphorylation of the polypeptide. Therefore, the effects of specific inhibitors were investigated. Staurosporine was first described as a potent inhibitor of protein kinase C, and inhibition by this compound has been considered diagnostic of the involvement of protein kinase C (31). However, the inhibitor was later shown to block a wide variety of protein kinases (8, 13, 21, 22, 25, 33), including several with tyrosine specificity (10, 21, 24, 30). There is also a group of protein kinases including casein kinase II (12, 21) that is relatively refractory to staurosporine inhibition.
Although the addition of staurosporine to infected cells produced a general decrease of the phosphorylation of all NSP5 forms, we did not observe a shift in the ratio of different forms. In rotavirus-infected cells, we observed a reduction of approximately 50% in the formation of 28- and 30- to 35-kDa forms, as measured by 32P incorporation. Phosphorylation of NSP5 protein expressed in COS-7 cells was also partially inhibited by staurosporine, whereas the autophosphorylation of the purified polypeptide was not. Together, these results show that part of the NSP5 phosphorylation in cells is produced by cellular protein kinases.
The casein kinase II inhibitor DRB (34) did not influence the phosphorylation of NSP5 when it was added to cell cultures infected with rotavirus or transfected with pcDNA-NSP5. In contrast, DRB partially inhibited autophosphorylation of immunoprecipitated NSP5 in vitro. We do not take this result as an indication that casein kinase II and NSP5 are coimmunoprecipitated. It is more likely that DRB is a weak inhibitor of NSP5 activity, but did not reach an inhibitory intracellular concentration when the compound was added to cultures. Analysis of the casein kinase II and NSP5 amino acid sequences did not reveal any similarity indicating that the active sites are related.
In the early phase of rotavirus infection, NSP5 becomes phosphorylated approximately 2 h after its synthesis (Fig. 3). This delay was probably not caused by susceptibility to phosphatases before NSP5 was translocated to viroplasms. After addition of okadaic acid to infected cells, the phosphorylation of NSP5 was still delayed approximately 2 h, although 32P incorporation into the 28- and 30- to 35-kDa forms was increased (Fig. 4). Moreover, the failure to induce full phosphorylation of the 26-kDa NSP5 precursor early in infection, when phosphatases were inhibited, probably reflects a low initial autophosphorylation activity of the polypeptide.
NSP5 immunoprecipitated from the infected cells did not show any autophosphorylation activity until 6 h postinfection, when highly phosphorylated forms of the protein had emerged in the infected cells (Fig. 3). Conversely, the in vitro protein kinase activity remained in NSP5 isolated at 10 h postinfection, when synthesis and phosphorylation of the polypeptide had ceased in the cells. These result suggests that the enzyme activity is regulated. At least part of the regulation seemed to be achieved by modification of the NSP5 polypeptide. Phosphorylation itself appears to be one factor of importance for the autophosphorylation activity in vitro. First, the 35-kDa form had the highest specific activity (Fig. 3), and second, NSP5 expressed from a vector had significant autophosphorylation activity only when it remained phosphorylated by inhibition of cellular phosphatases (Fig. 7).
The present study does not shed light on the function of NSP5 in rotavirus infection. No phosphorylation of other virus-encoded polypeptides has been identified. We are investigating whether cellular polypeptides are substrates of NSP5. So far, analysis by two-dimensional PAGE has not revealed any cellular phosphopeptides that appeared after expression of NSP5 in transfected COS-7 cells. In infected cells, NSP5 is produced in unusually large amounts to serve solely a catalytic function. Thus, it is possible that the highly phosphorylated polypeptide has a structural function in the organization of viroplasms.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported financially by the Swedish Medical Research Council and by the Swedish Agency for Research Cooperation with Developing Countries.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medical Biochemistry and Microbiology, Box 582, S-751 23 Uppsala, Sweden. Phone: 46-18-4714560. Fax: 46-18-509876. E-mail: Goran.Magnusson{at}imim.uu.se.
Present address: Instituto de Biotecnología, CICV-INTA
Castelar, CC77, 1708 Moron, Buenos Aires, Argentina.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Afrikanova, I.,
M. C. Miozzo,
S. Giambiagi, and O. Burrone.
1996.
Phosphorylation generates different forms of rotavirus NSP5.
J. Gen. Virol.
77:2059-2065 |
| 2. |
Bellinzoni, R. C.,
J. O. Blackhall,
N. M. Mattion,
M. K. Estes,
D. R. Snodgrass,
J. L. La Torre, and E. A. Scodeller.
1989.
Serological characterization of bovine rotaviruses isolated from dairy and beef herds in Argentina.
J. Clin. Microbiol.
27:2619-2623 |
| 3. | Bern, C., and R. I. Glass. 1994. Impact of diarrheal diseases worldwide, p. 1-26. In A. Z. Kapikian (ed.), Viral infections of the gastrointestinal tract. Marcel Dekker, Inc., New York, N.Y. |
| 4. | Bialojan, C., and A. Takai. 1988. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem. J. 256:283-290[Medline]. |
| 5. | Blackhall, J., A. Fuentes, K. Hansen, and G. Magnusson. 1997. Serine protein kinase activity associated with rotavirus phosphoprotein NSP5. J. Virol. 71:138-144[Abstract]. |
| 6. | Blackhall, J., A. Fuentes, J. L. La Torre, and G. Magnusson. 1996. Genetic stability of a porcine rotavirus RNA segment during repeated plaque isolation. Virology 225:181-190[Medline]. |
| 7. | Cohen, P., C. F. B. Holmes, and Y. Tsukitani. 1990. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem. Sci. 15:98-102[Medline]. |
| 8. | Elliot, L. H., S. E. Wilkinson, A. D. Sedgwick, C. H. Hill, G. Lawton, P. D. Davis, and J. S. Nixon. 1990. K252a is a potent and selective inhibitor of phosphorylase kinase. Biochem. Biophys. Res. Commun. 171:148-154[Medline]. |
| 9. |
Ericson, B. L.,
D. Y. Graham,
B. B. Mason, and M. K. Estes.
1982.
Identification, synthesis, and modifications of simian rotavirus SA11 polypeptides in infected cells.
J. Virol.
42:825-839 |
| 10. | Fallon, R. J. 1990. Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranes. Biochem. Biophys. Res. Commun. 170:1191-1196[Medline]. |
| 11. | González, S. A., and O. R. Burrone. 1991. Rotavirus NS26 is modified by addition of single O-linked residues of N-acetylglucosamine. Virology 182:8-16[Medline]. |
| 12. | Gschwendt, M., W. Kittstein, and F. Marks. 1994. Elongation factor-2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporine. FEBS Lett. 338:85-88[Medline]. |
| 13. | Herbert, J., E. Seban, and J. Maffrand. 1990. Characterization of specific binding sites for [3H]-staurosporine on various protein kinases. Biochem. Biophys. Res. Commun. 171:189-195[Medline]. |
| 14. | Kattoura, M. D., X. Chen, and J. T. Patton. 1994. The rotavirus RNA-binding protein NS35 (NSP2) forms 10S multimers and interacts with the viral RNA polymerase. Virology 202:803-813[Medline]. |
| 15. | Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685[Medline]. |
| 16. |
Loo, L. W. M.,
J. M. Berestecky,
M. Y. Kanemitsu, and A. F. Lau.
1995.
pp60src mediated phosphorylation of connexin 43, a gap junction protein.
J. Biol. Chem.
270:12751-12761 |
| 17. |
Mattion, N. M.,
R. C. Bellinzoni,
J. O. Blackhall,
J. L. La Torre, and E. A. Scodeller.
1989.
Antigenic characterization of swine rotaviruses in Argentina.
J. Clin. Microbiol.
27:795-798 |
| 18. | Mattion, N. M., J. Cohen, and M. K. Estes. 1994. The rotavirus proteins, p. 169-247. In A. Kapikian (ed.), Virus infections of the gastrointestinal tract, 2nd ed. Marcel Dekker, New York, N.Y. |
| 19. | Mattion, N. M., D. B. Mitchell, G. W. Both, and M. K. Estes. 1991. Expression of rotavirus proteins encoded by alternative open reading frames of genome segment 11. Virology 181:295-304[Medline]. |
| 20. |
McCrae, M. A., and G. P. Faulkner-Valle.
1981.
Molecular biology of rotaviruses. I. Characterization of basic growth parameters and pattern of macromolecular synthesis.
J. Virol.
39:490-496 |
| 21. | Meggio, F., A. Donella-Deana, M. Ruzzene, A. M. Brunati, L. Cesaro, B. Guerra, T. Meyer, H. Mett, D. Fabbro, P. Furet, G. Dobrowolska, and L. A. Pinna. 1995. Different susceptibility of protein kinases to staurosporine inhibition: kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem. 234:317-322[Medline]. |
| 22. | Meyer, T., U. Regenass, D. Fabbro, E. Alteri, J. Rösel, M. Müller, G. Caravatti, and A. Matter. 1989. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer 43:851-856[Medline]. |
| 23. |
Mitchell, D. B., and G. W. Both.
1988.
Simian rotavirus SA11 segment 11 contains overlapping reading frames.
Nucleic Acids Res.
16:6244 |
| 24. | Nakano, H., E. Kobyashi, I. Takahashi, T. Tamaoki, I. Kuzuu, and H. Iba. 1987. Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J. Antibiot. 40:706-708[Medline]. |
| 25. |
Niggli, V., and H. Keller.
1991.
On the role of protein kinases in regulating neutrophil actin association with the cytoskeleton.
J. Biol. Chem.
266:7927-7932 |
| 26. |
Patton, J. T.
1995.
Structure and function of the rotavirus RNA-binding proteins.
J. Gen. Virol.
76:2633-2644 |
| 27. |
Petrie, B. L.,
D. Y. Graham,
H. Hanssen, and M. K. Estes.
1982.
Localization of rotavirus antigens in infected cells by ultrastructural immunocytochemistry.
J. Gen. Virol.
63:457-467 |
| 28. | Petrie, B. L., H. B. Greenberg, D. Y. Graham, and M. K. Estes. 1984. Ultrastructural localization of rotavirus antigens using colloidal gold. Virus Res. 1:133-152[Medline]. |
| 29. | Poncet, D., P. Lindenbaum, R. L'Haridon, and J. Cohen. 1997. In vivo and in vitro phosphorylation of rotavirus NSP5 correlates with its localization in viroplasms. J. Virol. 71:34-41[Abstract]. |
| 30. |
Secrist, J. P.,
I. Sehgal,
G. Powis, and R. T. Abraham.
1990.
Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine.
J. Biol. Chem.
265:20394-20400 |
| 31. | Tamaoki, T., H. Nomoto, I. Takahashi, Y. Kato, M. Morimoto, and P. Tomita. 1986. Staurosporine, a potent inhibitor of phospholipid/Ca++-dependent protein kinase. Biochem. Biophys. Res. Commun. 135:397-402[Medline]. |
| 32. |
Welch, S. K.,
S. E. Crawford, and M. K. Estes.
1989.
Rotavirus SA11 genome segment 11 protein is a nonstructural phosphoprotein.
J. Virol.
63:3974-3982 |
| 33. | Yanagihara, N., E. Tachikawa, F. Izumi, S. Yasugawa, H. Yamamoto, and E. Miyamoto. 1991. Staurosporine: an effective inhibitor for Ca2+/calmodulin dependent protein kinase II. J. Neurochem. 56:294-298[Medline]. |
| 34. |
Zandomeni, R.,
M. C. Zandomeni,
D. Shugar, and R. Weinmann.
1986.
Casein kinase type II is involved in the inhibition by 5,6-dichloro-1- -D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription.
J. Biol. Chem.
261:3414-3419 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|